Blueprint Medicines

Third Rock Ventures expands, strengthens team

Wednesday, May 15, 2013

Third Rock Ventures, a venture capital firm focused on building healthcare companies, has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies and the overall strategy and direction of the firm.

[Read More]

Blueprint Medicines secures $40 Million in Series A for cancer treatment

Monday, April 11, 2011

Blueprint Medicines, a company focused on the molecular blueprint of cancer to develop cancer therapies, will close a $40 million Series A financing led by Third Rock Ventures. Proceeds from the financing will be used to develop new cancer therapies–using the company’s proprietary compound library and Insights-to-Validation Platform that target the driver molecular aberrations of cancer and emerging resistance mechanisms to certain cancer patients.

[Read More]